Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — H1 FY2024 Earnings Presentation
15 slides from Atomo Diagnostics's earnings presentation, Feb 26, 2024
Slide 1: For personal use only
For personal use only
Slide 2: Who is Atomo and what do we do?
WHO IS ATOMO AND WHAT DO WE DO? Our unique portfolio of test solutions are increasingly relevant in a diagnostic market transitioning to decentralised and at-home environments WHO IS ATOMO? WHAT DO WE DO? For personal use only Headquartered in Australia and with operations in South Africa, we Point
Slide 3: H1 FY24 - Profit & Loss
H1 FY24 - PROFIT & LOSS H1 H1 • Normalised revenue doubled period on period from <$1m to $1.92m, suggesting AUD (%) FY24($m) FY23($m) increasing demand for Atomo products and technology Revenue 1.92 1.36 41% Cost of sales (1.05) (1.12) • Normalised gross margin also improved materially when compared
Slide 4: H1 FY24 – Balance Sheet
H1 FY24 – BALANCE SHEET H1 FY24 FY23 AUD ($m) ($m) • Cash balance of $6.51m at 31 December 23 and debt free Cash and cash equivalents 6.51 6.47 For personal use only Trade and other receivables 1.31 1.82 • Capital raised during the period resulting in share capital increase of $2m net of costs Inven
Slide 5: H1 FY24 – Cash Flow
H1 FY24 – CASH FLOW • Cash receipts for the period totalled $4.8m For personal use only • ~$2m was received from product sales and an additional $761k received from the R&D tax rebate • Capital raised during the period net of transaction cost ~$2m • Cash payments for stock of $734k • Total Cash infl
Slide 6: Improving Revenues and Margins
IMPROVING REVENUES AND MARGINS Revenue Gross Profit 2.5 1.0 50% 45% For personal use only 2.0 0.8 40% 35% 1.5 0.6 30% $’000 $’000 25% 1.0 0.4 20% 15% 0.2 10% 0.5 5% - 0% - H1 FY22 H2 FY22 H1 FY23 H2 FY23 H1 FY24 H1 FY22 H2 FY22 H1 FY23 H2 FY23 H1 FY24 GP GP % Revenue (Excld Covid) (Excld Covid) • Re
Slide 7: Reducing Business Costs and Losses
REDUCING BUSINESS COSTS AND LOSSES Operating Expenditure* Rolling 12mth EBITDA* (Excl. COVID) 6.0 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 0.0 5.0 For personal use only (0.2) (0.4) 4.0 (0.6) $'000 3.0 (0.8) $’000 (1.0) 2.0 (1.2) (1.4) 1.0 (1.6) 0.0 (1.8) H1 FY22 H2 FY22 H1 FY23 H2 FY23 H1 FY24 (2.0) • OPEX c
Slide 8: Drivers of Market Acceptance
DRIVERS OF MARKET ACCEPTANCE Pascal has been independently validated* as delivering very significant reduction in user errors and high levels of user preference: This combination of offering unmatched ease of use and reliability in the hands of untrained users makes Atomo’s solutions increasingly at
Slide 9: Novel Technology – Increasingly Market Relevant
NOVEL TECHNOLOGY – INCREASINGLY MARKET RELEVANT Atomo offers partners a broad range of unique products that fundamentally improve rapid testing performance and user acceptance For personal use only BLOOD TEST SOLUTIONS SWAB TEST SOLUTIONS INTEGRATED REAGENT SOLUTIONS DIGITAL HEALTH SOLUTIONS A range
Slide 10: User-Friendly Rapid Testing Comes of Age
USER-FRIENDLY RAPID TESTING COMES OF AGE Post COVID and post US FDA approval of Pascal, Atomo is seeing increasing awareness of and interest in its novel integrated rapid test solutions Re-emerging OEM Technology demand post COVID: Existing OEM customers NG Biotech and Lumos Diagnostics both reorder
Slide 11: Atomo's HIV Business
ATOMO’S HIV BUSINESS Atomo saw good momentum in its HIV business develop this last year due to two main trends: • Increasing adoption of consumer self-test through mainstream retail channels • Recognition by public health of the need to utilise self-test to manage HIV For personal use only Atomo’s c
Slide 12: Atomo's Australian HIV Business
ATOMO’S AUSTRALIAN HIV BUSINESS HIV Sales (Australia Only) H1 FY24 100 90 80 70 For personal use only $'000 AUD 60 50 40 30 20 10 - Jul-23 Aug-23 Sep-23 Oct-23 Nov-23 Dec-23 HIV - Aus Revenue Over the last two years Atomo has helped pilot innovative 30 Nov 2023: Based on a growing body of Increased
Slide 13: First Blood Based Pregnancy Self-Test to Market
FIRST BLOOD BASED PREGNANCY SELF-TEST PREGNANCY TO MARKET* The AtomoNOW rapid pregnancy test is a unique solution in a very large addressable consumer test market Our blood-based pregnancy test offers a number of significant advantages over traditional urine based rapid tests: For personal use only
Slide 14: Key Priorities and Growth Drivers
KEY PRIORITIES AND GROWTH DRIVERS Continued growth of HIV business revenues and margins: • Extension of the Newfoundland agreement covering Europe for a further 5 years For personal use only • Expansion of HIV ST into public health in Australia as policy opens up funded demand Expansion of OEM Casse
Slide 15: Disclaimer
DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on connection with the opportunity outlined in this presentation and no representation or information available as at the date of this presentation. The information in this presentation warranty is made in re